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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
Primary objectives
1. To assess the efﬁcacy and safety of antidepressants for managing anxiety and depression in IBD
2. To assess the efﬁcacy and safety of antidepressants for managing quality of life in IBD
Secondary objectives
1. To assess the efﬁcacy and safety of antidepressants for managing disease activity in IBD
B A C K G R O U N D
Description of the condition
Inﬂammatory bowel disease (IBD) is a chronic, relapsing and life-
limiting condition of the gastrointestinal tract. The aetiology of
IBD is thought to involve an inappropriate immune response to
intestinal microbiota, triggered by environmental factors, in ge-
netically susceptible people. The typical symptoms of IBD include
diarrhoea, urgency of defecation, abdominal pain and cramping,
fatigue, and weight loss. Currently, IBD affects 2.2 million people
in Europe (Loftus 2004), 1.4 million people in the US (CCFA
2012), 233,000 people in Canada (Rocchi 2012), and over 75,000
people in Australia (CCA 2015).
IBD is associated with a signiﬁcant psychosocial burden. People
with IBD have a higher life-time prevalence of depression com-
pared to the general community, with estimated rates of 27%
in persons with IBD compared to 12% in the general popula-
tion (Walker 2008). Psychological stress has been found to pre-
dict symptomatic disease course (Bernstein 2011), and is also
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linked to increased inﬂammation (Maunder 2008). Associations
between symptoms of depression and clinical recurrence over
time (Mikocka-Walus 2016), higher hospitalisation rates (Van
Langenberg 2010), and lower adherence to treatment (Nigro
2001), have also been suggested.
Despite signiﬁcant mental comorbidities with IBD and impact
on disease course, mental disorders are not routinely treated in
this population. In fact, less than 40% of those with IBD report-
ing mental symptoms receive psychotherapy (Bennebroek Evertsz
2012). Poor access to psychologists may contribute to this ﬁnding.
In the UK, for example, only a fraction of IBD services (12%)
have access to clinical psychology (RCP 2014). However, there is
also poor evidence that psychotherapies are effective for mental
disorders and any physical complaints in this population (Timmer
2011). There are reports that cognitive-behavioural therapy may
provide some beneﬁt in patients with IBD (Knowles 2013). How-
ever, only a few studies are available, and recent trials demonstrate
only short-term improvements in quality of life (McCombie 2016;
Mikocka-Walus 2015).
On the other hand, depending on the population, 10% to 30%
of IBD patients take antidepressants (Fuller-Thomson 2006;
Haapamaki 2013; Mikocka-Walus 2012), and thus given the
prevalence of depression in IBD (Walker 2008), it may be con-
cluded that the majority of IBD patients reporting mental symp-
toms who are treated for these symptoms receive antidepressants.
However, studies have shown that those IBD patients who receive
antidepressants do not necessarily suffer from depression but of-
ten are treated for pain, insomnia or functional bowel symptoms
which overlap with IBD (Mikocka-Walus 2007; Mikocka-Walus
2012). This resembles treatment for functional gut disorders such
as irritable bowel syndrome, where there is good evidence of an-
tidepressants’ efﬁcacy for physical symptoms (Ford 2009; Ford
2014). However, while antidepressants are used in IBD, the ef-
ﬁcacy of this intervention in this population has not been estab-
lished to date.
Description of the intervention
Antidepressants are drugs used to treat depression and other men-
tal disorders such as anxiety. While lithium was known in the 19th
century, it wasn’t introduced to common psychiatry practice until
the 1950s (Shorter 2009). Other antidepressants - monoamine
oxidase inhibitors and tricyclics were also introduced in the 1950s
while tetracyclics were introduced in the 1970s. Presently, the
most commonly used antidepressants are selective serotonin reup-
take inhibitors (SSRIs) which were introduced in the 1980s. Sero-
tonin-norepinephrine reuptake inhibitors (SNRI) became avail-
able in the 1990s. Other less commonly known groups of an-
tidepressants include: heterocyclics, norepinephrine reuptake in-
hibitors (NARIs), norepinephrine-dopamine reuptake inhibitors
(NDRIs), noradrenergic and speciﬁc serotonergic antidepressants
(NaASSAs), and serotonin antagonist and reuptake inhibitors
(SARIs).
Dosage regimens differ between the different classes and individ-
ual antidepressants, and depend on the severity of symptoms. An-
tidepressants are usually taken daily (either morning or night) and
the treatment ranges from several months to several years or even
lifetime use. The efﬁcacy of older antidepressants (e.g. tricyclics)
andnewer, second-generation antidepressants (e.g. SSRI) is similar
(Williams 2000). However, the use of ﬁrst generation antidepres-
sants is associated with more serious adverse events, with increased
lethality with overdose (Gartlehner 2007; Gartlehner 2011), and
thus these agents are no longer ﬁrst line treatment for depression
or anxiety.
No antidepressants are currently approved by regulatory agen-
cies for speciﬁcally treating anxiety and depression comorbid with
IBD, to manage physical symptoms of IBD or to reduce bowel in-
ﬂammation. However, some antidepressants have indications for
treatment of pain in chronic conditions. For example, duloxetine
has an indication for diabetic peripheral neuropathy (AMH 2012).
How the intervention might work
Antidepressants are thought to work through compensating for
transmitter deﬁcits in the brain, which are considered to be the
underlying cause of depression (Ritter 2015). Antidepressants can
either inhibit the reuptake of neurotransmitters from the synaptic
cleft or inhibit the metabolism of neurotransmitters. Thus, for ex-
ample, tricyclics inhibit the uptake of noradrenaline or serotonin
or both; SSRIs inhibit uptake of serotonin while SNRIs inhibit
uptake of both noradrenaline and serotonin, and monoamine oxi-
dase inhibitors inhibit themetabolism ofmono-amine neurotrans-
mitters such as serotonin. However, it is also hypothesized that
antidepressants may help treat depression due to immunoregula-
tory effects (Maes 2001). A signiﬁcant drop in serum C-reactive
protein concentrations (independent of depressive symptoms be-
ing resolved) has been observed following four weeks of treatment
with SSRIs (O’Brien 2006). Even in healthy volunteers, antide-
pressants have been shown to improve immunoregulatory activity
(Szuster-Ciesielska 2003); and in sufferers of chronic inﬂamma-
tory conditions, antidepressants are reported to reduce the need
for steroids (Brown 2005), and improve overall immune function
(Krommydas 2005).
Given the immunoregulatory effect of antidepressants, it is pos-
sible that when given to patients with inﬂammatory conditions
such as IBD, antidepressants can exert an effect on inﬂamma-
tion outside the brain and thus improve not only mood but also
bowel symptoms, by extending or inducing remission. Animal
studies examining models of colitis can serve as a proof of concept
(Mikocka-Walus 2009). For example, mice receiving desipramine
(a tricyclic antidepressant) have signiﬁcantly reduced microscopic
damage (P < 0.05) and attenuation of colonic myeloperoxidase
activity ( P < 0.05) when compared to placebo (Varghese 2006).
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Furthermore, serum Il-1β concentrations were signiﬁcantly lower
in rats receiving 10 mg ﬂuoxetine (an SSRI), 20 mg ﬂuoxetine,
20 mg desipramine or 10 mg desipramine compared to controls
(all P < 0.001) (Guemei 2008). Similarly, reductions in serum tu-
mour necrosis factor-alpha were observed in rats receiving either
desipramine or ﬂuoxetine (10 or 20 mg) compared to controls (all
P < 0.001). Thus, antidepressants can induce an anti-inﬂamma-
tory response which is not related to antidepressive effects.
Further, treatments which improve inﬂammation in IBD such as
biologics are known to also improve quality of life (Feagan 2007).
Thus, it is hypothesised that antidepressants can reduce symptoms
of anxiety and depression and improve quality of life in IBD. It
is further hypothesised that, similarly to what occurs in animal
models where antidepressants have been shown to have anti-in-
ﬂammatory properties, antidepressants may induce remission of
IBD and reduce the number of ﬂares in humans.
Why it is important to do this review
There is a growing interest in mental health and antidepressant use
in chronic illness, to manage comorbid depression as well as physi-
cal symptoms, with recentCochrane systematic reviews conducted
on diabetes (Baumeister 2014), coronary artery disease (CAD)
(Baumeister 2011), and functional gut disorders (Ruepert 2011).
These reviews have shown improved glycaemic control after the
use of SSRIs versus placebo in patients with diabetes (Baumeister
2014); improvements in depression, reduction in hospitalisations
and emergency room visits (though no beneﬁcial effects on mor-
tality, cardiac events or quality of life) after SSRIs use compared to
placebo inCAD (Baumeister 2011); and improvements in abdom-
inal pain and symptoms (after tricyclics as compared to placebo)
and in global assessment (after SSRIs as compared to placebo) in
irritable bowel syndrome (Ruepert 2011). However, there is cur-
rently no Cochrane systematic review exploring the role of antide-
pressants in IBD.
The only other systematic review on the use of antidepressants in
IBD was conducted in 2005 and identiﬁed 12 uncontrolled stud-
ies (Mikocka-Walus 2006).While the review observed a beneﬁcial
effect of antidepressants on mental and physical status of IBD pa-
tients, the available research was of low quality, making it impossi-
ble to provide a deﬁnitive statement on the efﬁcacy of antidepres-
sants for improving outcomes in patients with IBD. Since 2005
when the last systematic review was conducted several studies on
antidepressant use in IBD have been published, including two re-
cent trials (Daghaghzadeh 2015; Mikocka-Walus 2017). It is now
time to review current evidence on the effectiveness and safety of
antidepressants for mood and disease activity in IBD patients.
Given the widespread use of antidepressants in IBD (Fuller-
Thomson 2006; Haapamaki 2013; Mikocka-Walus 2012), and
the potential for improvement in immunoregulatory activity
(Krommydas 2005), it is important to assess the efﬁcacy and safety
of antidepressants in IBD. There is currently no cure for IBD and
while pharmacotherapy with several agents (i.e. 5-aminosalicylic
acid (5ASA), azathioprine (AZA), and biologics) has been shown
to maintain remission (D’Haens 2008), extending remission still
presents a challenge to clinicians. This review will thus explore the
adjuvant role of antidepressants in IBD.
O B J E C T I V E S
Primary objectives
1. To assess the efﬁcacy and safety of antidepressants for managing
anxiety and depression in IBD
2. To assess the efﬁcacy and safety of antidepressants for managing
quality of life in IBD
Secondary objectives
1. To assess the efﬁcacy and safety of antidepressants for managing
disease activity in IBD
M E T H O D S
Criteria for considering studies for this review
Types of studies
All published and unpublished quantitative studies including: ran-
domised controlled trials, and non-randomised controlled studies,
prospective and retrospective studies including cohort, case con-
trol, cross-sectional and audit studies, are eligible for inclusion.
Studies without a comparison group will be excluded.
Types of participants
Humans, clinically diagnosed with IBD of any type (i.e. Crohn’s
disease, ulcerative colitis or indeterminate colitis) - according to
standard practice (i.e. a combination of clinical, radiologic, endo-
scopic and histologic grounds).
Types of interventions
All types of antidepressants (in any dose) will be included; e.g.
· SSRIs (citalopram, escitalopram, ﬂuoxetine, ﬂuvoxamine, parox-
etine, sertraline);
·Tricyclics (amitriptyline, clomipramine, desipramine, dothiepin,
doxepin, imipramine, lofepramine, nortriptyline, protriptyline,
trimipramine);
· Heterocyclics (mianserin);
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· MAO inhibitors (isocarboxazid, phenelzine, tranylcypromine,
brofaromine, moclobemide, tyrima);
· NARIs (reboxetine);
· NDRIs (amineptine, buproprion);
· SNRIs (duloxetine, milnacipran, venlafaxine);
· NASSAs (mirtazapine);
· SARIs (trazodone); and
· Other unclassiﬁed antidepressants (agomelatine, vilazodone).
Any comparator including any of the following will be considered
for inclusion:
· No intervention;
· Placebo;
· Standard care/treatment as usual;
· Surgery;
· Alternative interventions used to treat depression and anxiety,
e.g. anxiolytics, psychotherapy;
· Another antidepressant; and
· Any other active comparators.
Types of outcome measures
Primary outcomes
Efficacy
1. Changes in anxiety and depression as measured by any validated
anxiety or depression scale; and
2. Changes in quality of life as measured by any validated quality
of life scale.
Safety
1. Adverse events;
2. Serious adverse events; and
3. Study withdrawal due to adverse events.
Secondary outcomes
1. Clinical remission at trial completion or at follow-up comple-
tion for induction of remission studies (as appropriate, and ideally,
controlling for baseline disease activity); and
2. Relapse at trial completion or at follow-up completion formain-
tenance of remission studies (as appropriate, and ideally, control-
ling for baseline disease activity).
Both will be assessed using any commonly used disease activ-
ity scales (e.g. Crohn’s Disease Activity Index (CDAI)), or by
colonoscopy (e.g. Crohn’s Disease Endoscopic Index of Severity
(CDEIS) or Simple Endoscopic Scale for Crohn’s Disease (SES-
CD)).
Tertiary outcomes
1. Changes in pain severity as established using any validated pain
scale; and
2. Changes in hospital admissions, surgery, need for steroid treat-
ment.
Search methods for identification of studies
Electronic searches
Wewill search the following sources from inception to present and
without language restrictions:
·MEDLINE via PubMed (Appendix 1);
· EMBASE (Appendix 2);
· CINAHL (Appendix 3);
· PsycINFO (Appendix 4);
· CENTRAL; and
· The Cochrane IBD Group Specialized Trials Register.
We will search trial registries to identify any unpublished or on-
going studies. These registries will include:
· The WHO Trials portal (ICTRP)
· ClinicalTrials.gov
· The National Research Register
We will search conference proceedings from inception to date to
identify studies published in abstract form. These conferences will
include:
· Digestive Disease Week;
· United European Gastroenterology Week;
· European Crohn’s and Colitis Organisation; and
· Advances in IBD.
We will search the grey literature database Open Grey to identify
studies not indexed in the major databases.
Searching other resources
We will contact trial authors and search the reference lists of in-
cluded studies and applicable systematic reviews to identify studies
missed by the database searches.
Data collection and analysis
Selection of studies
Two authors (AMW, AF) will independently screen titles and ab-
stracts identiﬁed by the search and exclude those studies not meet-
ing the selection criteria. Full text reports will be obtained for all
the studies deemed eligible and read independently by two au-
thors. We will contact the study authors if information pertaining
to eligibility is missing. In cases where the two authors cannot
reach consensus on study eligibility, a third investigator (AE) will
be consulted.
Data extraction and management
Data will be independently extracted by two authors (AMW, SP).
We will resolve any disagreements by consensus and, if this cannot
be reached, a third author (SK) will be asked to arbitrate.
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We will extract the following information:
1. General study information: authors, year, country;
2. Method: design (including details such as: randomisation, al-
location concealment, duration, follow-up), setting, recruitment,
intervention (type of antidepressant, dose, frequency, type of con-
trols, adherence), clinical measures (e.g. disease activity measure,
measures of anxiety/depression), sample size calculation;
3. Participants: number of participants, age, sex, IBD type, per
cent in remission; and
4. Outcomes: descriptives (mean/SD or median/inter-quartile
range (or range), frequency (%) plus accompanying statistics, e.g.
OR, P value) for primary and secondary outcomemeasures at time
points, adverse events, and loss to follow-up.
Where necessary, we will contact study authors about missing or
unclear information.
Assessment of risk of bias in included studies
The variety of study designs included in this review necessitate
the use of several different quality assessment tools. For ran-
domised trials, we will use the Cochrane Risk of Bias tool (Higgins
2011). We will examine the following types of bias: selection bias
(sequence generation and allocation sequence concealment, two
items), performance bias (blinding of participants and personnel,
two items), detection bias (blinding of outcome assessment, one
item), attrition bias (incomplete outcome data at short-term (two
to six weeks) and at long-term (greater than six weeks, two items),
reporting bias (selective outcome reporting, one item). Each item
will be addressed with either ‘Low risk’, ‘High risk’ or ’Unclear
risk’. For observational studies (case-control and cohorts), we will
use the Newcastle-Ottawa Scale (Wells 2000), for which a study
can score a possible of eight points, with a higher score consistent
with a lower risk. A National Institute of Health (NIH) quality
assessment tool will be used to assess the quality of cross-sectional
surveys (NIH 2016). For audits, we will use the NIH quality as-
sessment tool (NIH 2014). Both of the NIH tools give a ﬁnal
quality rating of ‘Good’, ‘Fair’ or ‘Poor’.
In addition, we will use the GRADE approach to evaluate the
overall quality of the evidence supporting the primary outcomes
and selected secondary outcomes (Guyatt 2008). Evidence from
randomised trials starts as high quality but may be downgraded
due to within-study risk of bias (methodological quality), indi-
rect evidence, unexplained heterogeneity, imprecision of effect es-
timates and risk of publication bias. Each outcome will be assigned
one of the following scores: high quality (future research unlikely
to change conﬁdence in the estimate); moderate quality (future
research likely to impact conﬁdence in the estimate); low quality
(future research very likely to impact conﬁdence in the estimate);
very low quality (the estimate is uncertain).
We will prepare a summary of ﬁndings table for the following
outcomes:
· Anxiety and depression;
· Quality of life;
· IBD remission at trial completion or at follow-up completion;
· IBD relapse at trial completion or at follow-up completion;
· Pain;
· Adverse events; and
· Serious adverse events.
Measures of treatment effect
We will use RevMan for data analysis. For dichotomous outcomes
we will calculate the odds ratio (OR) and corresponding 95%
conﬁdence interval (CI). We will calculate the number needed
to treat (NNT) and risk difference (RD) where appropriate. For
continuous outcomes we will calculate the mean difference (MD)
and corresponding 95% CI.
Unit of analysis issues
Where the efﬁcacy of multiple antidepressants (on IBD activity)
is compared, we will split the shared comparison group (e.g. stan-
dard care or psychotherapy) equally between the antidepressants
arms as comparison groups. Cross-over trials will only be included
when antidepressant and comparator data can be extracted from
the ﬁrst treatment period or when the sufﬁcient wash-out period
occurs between treatment periods (e.g. two weeks for all antide-
pressants except for ﬂuoxetine where four weeks are required in
light of the long plasma half-life). When the wash-out period is
deemed sufﬁcient and if the standard error of the mean difference
in response between groups can be obtained (e.g. from the trial re-
port or through averaging the relevant statistics from other studies
with comparable control conditions (Elbourne 2002)), data from
both periods will be presented.
Dealing with missing data
We will adhere to intention-to-treat principle. In the case of di-
chotomous data when treatment response is compared, we will
include the total number of participants randomised to each com-
parison group (as the denominator). In the analyses of treatment
response, only the data from trials reporting a group size prior to
drop-outs will be included. For continuous outcome measures, we
will include summary statistics derived frommixed-effectsmodels,
the last observation carried forward, and observed cases summary
statistics. This is dictated by the notion that mixed-effects models
are considered less biased than the analyses of the last observation
carried forward (Verbeke 2000).
Assessment of heterogeneity
We will assess clinical homogeneity with respect to the type of
IBD (i.e.Crohn’s disease versus ulcerative colitis or indeterminate
colitis) and treatment response (remission/ﬂare, improved depres-
sion rates, etc) using the forest plot of the relative risk. We will
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also review the results of Chi2 tests. A P value of less than 0.10
will be considered evidence of statistically signiﬁcant heterogene-
ity (assuming the low power of the Chi2 statistic when few trials
are available) (Deeks 2011). We will use the I2 statistic and its
conﬁdence interval to assess heterogeneity across trials (Higgins
2003). An I2 statistic greater than 30% will be considered moder-
ate heterogeneity and greater than 50% will be considered severe
heterogeneity.
Subgroup differences in continuous measures of antidepressant
efﬁcacy will be investigated using Deeks’ stratiﬁed test of hetero-
geneity (Deeks 2001). Herein the sum of the Chi2 statistics for
each of the subgroups included in the study is subtracted from
the Chi2 statistic for all the studies, to provide a measure (Qb) of
heterogeneity between groups. As different antidepressants may
exert different effects, we will stratify all of the outcome compar-
isons by the individual antidepressant used (excluding subgroup
and sensitivity analyses).
Assessment of reporting biases
Small-sample effects will be investigated by visual inspection of a
funnel plot of treatment response (Sterne 2011). This will only
take place if we identify at least 10 studies as the method is not
robust with fewer studies (Egger 1997).
Data synthesis
We will calculate the pooled OR and corresponding 95% CI for
dichotomous outcomes. For continuous outcomes, we will calcu-
late the pooled MD or standardised mean difference (SMD) with
95% CI as appropriate. When necessary, dichotomous and con-
tinuous variables will be combined using the standard Cochrane
procedure (InOR = SMD X pi /
√
3) (Deeks 2011). This is likely
to occur in the case of scores on depression and anxiety scales such
as the Hospital Anxiety and Depression Scale which are reported
as either means or percentages (i.e. with a score above a speciﬁed
cut-off value) or both.
Odds ratios will be produced and converted to an approximate
risk ratio (RR) with 95% CIs for interpretation, using the formula
RR = OR / [1 - ACR X (1 - OR)], where ACR is the assumed
control group risk. We will obtain categorical and continuous
treatment effects from a random-effects model. We will express
the outcomes as an average effect size for each subgroup and 95%
CIs. In longitudinal studies, we will combine the data from the
ﬁnal assessment point for all the outcome measures. We will use
study design to stratify comparisons of global treatment response
and improvements in the outcomes.
Subgroup analysis and investigation of heterogeneity
If sufﬁcient data are available, subgroup analysis will be conducted
for the following subgroups:
IBD subtype: Crohn’s disease versus ulcerative colitis or indeter-
minate colitis;
Sex: Male versus female; and
Types of antidepressants: SSRI versus tricyclics.
Sensitivity analysis
Sensitivity analyses will be performed to check the robustness of
our conclusions for the meta-analysis of the primary outcome (i.e.
proportion in remission). We will follow the same procedure as
we applied in our previous protocol on a similar topic (Gordon
2013):
1. We will assess whether treatment response varies as a function
of the use of treatment response versus non-response as outcomes.
Treatment response may produce less consistent outcome statistics
than non-response in cases when the control group event rate is
greater than 50% (Deeks 2002). This analysis will only be con-
ducted if the majority of studies report a control group event rate
greater than 50%.
2. We will also conduct a ’worst case/best case’ analysis to examine
the impact of the exclusion of those lost to follow-up on treat-
ment efﬁcacy effect estimates (Deeks 2011). Herein, for the worst
case scenario, all the missing data for the treatment group will be
recorded as non-responders. For the best case scenario, all missing
data in the control group will be considered non-responders. If the
effect estimates of treatment efﬁcacy do not differ between these
two comparisons, we will conclude that missing data in the studies
do not have a signiﬁcant impact on outcomes.
A C K N OW L E D G E M E N T S
Partial funding for the Cochrane IBD Group (April 1, 2016 -
March 31, 2018) has been provided byCrohn’s andColitis Canada
(CCC).
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. (Inﬂammatory bowel disease* or IBD).mp.
2. Exp Crohn disease/ or crohn*.mp.
3. Exp ulcerative colitis/ or (ulcerat* and colitis)
4. Exp enterocolitis/ or pancolitis/ or proctitis/ or proctocolitis/
5. 1 or 2 or 3 or 4
6. Exp antidepress*.mp or anti-depress*.mp or (anti depress*)
7. Exp MAO*.mp or (monoamine oxidase inhibit*).mp
8. Exp (serotonin or norepinephrine or noradrenaline or neurotransmitt* or dopamin*).mp or (uptake or reuptake or re-uptake or “re
uptake”).mp
9. Exp NARI*.mp or NDRI*.mp or SARI*.mp or SNRI*.mp or SSRI*.mp or tetracyclic*.mp or TCA*.mp or tricyclic*.mp or
pharmacotherap*.mp or psychotropic*.mp or (drug therapy).mp or thymoanaleptic*.mp or thymoleptic*.mp or atypical.mp
10. (Agomelatine or Alaproclate or Amoxapine or Amineptine or Amitriptylin* or Amitriptylinoxide or Atomoxetine or Beﬂox-
atone or Benactyzine or Bifemelane or Binospirone or Brofaromine or Bupropion or Amfebutamone or Butriptyline or Caroxa-
zone or Cianopramine or Cilobamine or Cimoxatone or Citalopram or Chlorimipramin* or Clomipramin* or Chlomipramin* or
Clomipramine or Clorgyline or Clovoxamine or CX157 or Tyrima or Demexiptiline or Deprenyl or Desipramin* or Pertofrane or
Desvenlafaxine or Dibenzepin or Diclofensine or Dimetacrin* or Dosulepin or Dothiepin or Doxepin or Duloxetine or Desvenlafaxine
or DVS-233 or Escitalopram or Etoperidone or Femoxetine or Fluotracen or Fluoxetine or Fluvoxamine or Gepirone or Imipramin* or
Iprindole or Iproniazid* or Iproclozide or Ipsapirone or Isocarboxazid* or Levomilnacipran or Lofepramin* or Lu AA21004* or Vor-
tioxetine or Lu AA24530* or LY2216684* or Edivoxetine or Maprotiline or medifoxamine or Melitracen or Metapramine or Mianserin
or Milnacipran or Minaprine or Mirtazapine or Moclobemide or Nefazodone or Nialamide or Nitroxazepine or Nomifensine or Nor-
fenﬂuramine or Nortriptylin* or Noxiptilin* or Opipramol or Oxaﬂozane or Oxitriptan or Paroxetine or Phenelzine or Pheniprazine
or Pipofezine or Pirlindole or Pivagabine or Pizotyline or Propizepine or Protriptylin* or Quinupramine or Reboxetine or Rolipram or
Scopolamine or Selegiline or Sertraline or Setiptiline or Teciptiline or Thozalinone or Tianeptin*or Toloxatone or Tranylcypromin* or
Trazodone or Trimipramine or Tryptophan or Venlafaxine or Viloxazine or Vilazodone or Viqualine or Vortioxetine or Zalospirone or
Zimeldine).mp
11. 6 or 7 or 8 or 9 or 10
12. 5 AND 11
Appendix 2. EMBASE search strategy
1. (Inﬂammatory bowel disease* or IBD).mp.
2. Exp Crohn disease/ or crohn*.mp.
3. Exp ulcerative colitis/ or (ulcerat* and colitis)
4. Exp enterocolitis/ or pancolitis/ or proctitis/ or proctocolitis/
5. 1 or 2 or 3 or 4
6. Exp antidepress*.mp or anti-depress*.mp or (anti depress*)
7. Exp MAO*.mp or (monoamine oxidase inhibit*).mp
8. Exp (serotonin or norepinephrine or noradrenaline or neurotransmitt* or dopamin*).mp or (uptake or reuptake or re-uptake or “re
uptake”).mp
9. Exp NARI*.mp or NDRI*.mp or SARI*.mp or SNRI*.mp or SSRI*.mp or tetracyclic*.mp or TCA*.mp or tricyclic*.mp or
pharmacotherap*.mp or psychotropic*.mp or (drug therapy).mp or thymoanaleptic*.mp or thymoleptic*.mp or atypical.mp
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atone or Benactyzine or Bifemelane or Binospirone or Brofaromine or Bupropion or Amfebutamone or Butriptyline or Caroxa-
zone or Cianopramine or Cilobamine or Cimoxatone or Citalopram or Chlorimipramin* or Clomipramin* or Chlomipramin* or
Clomipramine or Clorgyline or Clovoxamine or CX157 or Tyrima or Demexiptiline or Deprenyl or Desipramin* or Pertofrane or
Desvenlafaxine or Dibenzepin or Diclofensine or Dimetacrin* or Dosulepin or Dothiepin or Doxepin or Duloxetine or Desvenlafaxine
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tioxetine or Lu AA24530* or LY2216684* or Edivoxetine or Maprotiline or medifoxamine or Melitracen or Metapramine or Mianserin
or Milnacipran or Minaprine or Mirtazapine or Moclobemide or Nefazodone or Nialamide or Nitroxazepine or Nomifensine or Nor-
fenﬂuramine or Nortriptylin* or Noxiptilin* or Opipramol or Oxaﬂozane or Oxitriptan or Paroxetine or Phenelzine or Pheniprazine
or Pipofezine or Pirlindole or Pivagabine or Pizotyline or Propizepine or Protriptylin* or Quinupramine or Reboxetine or Rolipram or
Scopolamine or Selegiline or Sertraline or Setiptiline or Teciptiline or Thozalinone or Tianeptin*or Toloxatone or Tranylcypromin* or
Trazodone or Trimipramine or Tryptophan or Venlafaxine or Viloxazine or Vilazodone or Viqualine or Vortioxetine or Zalospirone or
Zimeldine).mp
11. 6 or 7 or 8 or 9 or 10
5 AND 11
Appendix 3. CINAHL search strategy
1. (TI inﬂammatory bowel or AB inﬂammatory bowel) OR (TI IBD or AB IBD) OR (TI Crohn* or AB Crohn*) OR (TI CD or AB
CD) OR (TI ulcerative colitis or AB ulcerative colitis) OR (TI colitis* or AB colitis*) OR (TI UC or AB UC) OR (TI enterocolitis or
AB enterocolitis) OR (TI pancolitis or AB pancolitis) OR (TI proctitis or AB proctitis) OR (TI proctocolitis or AB proctocolitis) OR
(TI ileitis or AB ileitis) OR (TI ileocolitis or AB ileocolitis) OR (TI enteritis or AB enteritis)
2. (TI antidepress* or AB antidepress*) OR (TI anti-depress* or AB anti-depress*) OR (TI anti depress* or AB anti depress*) OR
(TI MAO* or AB MAO*) OR (TI monoamine oxidase inhibit* or AB monoamine oxidase inhibit*) OR (TI serotonin* or AB
serotonin*) OR (TI norepinephrine or AB norepinephrine) OR (TI noradrenaline or AB noradrenaline) OR (TI neurotransmitt* or
AB neurotransmitt*) OR (TI dopamin* or AB dopamin*) OR (TI NARI* or AB NARI*) OR (TI NDRI* or AB NDRI*) OR (TI
SARI* or AB SARI*) OR (TI SNRI* or AB SNRI*) OR (TI SSRI* or AB SSRI*) OR (TI tetracyclic* or AB tetracyclic*) OR (TI
TCA* or AB TCA*) OR (TI tricyclic* or AB tricyclic*) OR (TI pharmacotherap* or AB pharmacotherap*) OR (TI psychotropic* or
AB psychotropic*) OR (TI drug therapy or AB drug therapy) OR (TI thymoanaleptic* or AB thymoanaleptic*) OR (TI thymoleptic*
or AB thymoleptic*) OR (TI atypical or AB atypical)
Appendix 4. PsycINFO search strategy
TI (Inﬂammatory bowelOR IBDORCrohn*ORulcerative colitisOR enterocolitisORpancolitisORproctitisORproctocolitis) AND
TI (antidepress* OR anti-depress* OR anti depress* OR MAO* OR monoamine oxidase inhibit* OR serotonin OR norepinephrine
OR noradrenaline OR neurotransmitt* OR dopamin* OR NARI* OR NDRI* OR SARI* OR SNRI* OR SSRI* OR tetracyclic* OR
TCA* OR tricyclic* OR pharmacotherap* OR psychotropic* OR drug therapy OR thymoanaleptic* OR thymoleptic* OR atypical)
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